KR20240127981A - P53 종양 항원을 표적화하는 mana바디 및 이의 사용 방법 - Google Patents

P53 종양 항원을 표적화하는 mana바디 및 이의 사용 방법 Download PDF

Info

Publication number
KR20240127981A
KR20240127981A KR1020247021279A KR20247021279A KR20240127981A KR 20240127981 A KR20240127981 A KR 20240127981A KR 1020247021279 A KR1020247021279 A KR 1020247021279A KR 20247021279 A KR20247021279 A KR 20247021279A KR 20240127981 A KR20240127981 A KR 20240127981A
Authority
KR
South Korea
Prior art keywords
seq
scfv
cancer
antigen
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247021279A
Other languages
English (en)
Korean (ko)
Inventor
베르트 보겔스타인
케네쓰 더블유. 킨즐러
니콜라스 파파도포울로스
쉬빈 쪼우
사라 디나폴리
에밀리 한-청 시우에
브라이언 제이. 모그
캐써린 엠. 롸이트
산드라 비. 가벨리
Original Assignee
더 존스 홉킨스 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 존스 홉킨스 유니버시티 filed Critical 더 존스 홉킨스 유니버시티
Publication of KR20240127981A publication Critical patent/KR20240127981A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020247021279A 2021-12-16 2022-12-15 P53 종양 항원을 표적화하는 mana바디 및 이의 사용 방법 Pending KR20240127981A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163290353P 2021-12-16 2021-12-16
US63/290,353 2021-12-16
PCT/US2022/053065 WO2023114430A1 (en) 2021-12-16 2022-12-15 Manabodies targeting p53 tumor antigens and methods of using

Publications (1)

Publication Number Publication Date
KR20240127981A true KR20240127981A (ko) 2024-08-23

Family

ID=86773477

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247021279A Pending KR20240127981A (ko) 2021-12-16 2022-12-15 P53 종양 항원을 표적화하는 mana바디 및 이의 사용 방법

Country Status (10)

Country Link
US (1) US20250034252A1 (https=)
EP (1) EP4448583A4 (https=)
JP (1) JP2024546923A (https=)
KR (1) KR20240127981A (https=)
CN (1) CN118541396A (https=)
AU (1) AU2022415459A1 (https=)
CA (1) CA3242393A1 (https=)
IL (1) IL313491A (https=)
MX (1) MX2024007456A (https=)
WO (1) WO2023114430A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025106598A1 (en) * 2023-11-13 2025-05-22 Clasp Therapeutics, Inc. Modified mana-tces targeting tumor antigens and engaging t cell receptors, and methods of using thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL294183B2 (en) * 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
GB201617564D0 (en) * 2016-10-17 2016-11-30 Agency For Science Technology And Research And National University Of Singapore And Singapore Health Anti-p53 antibodies
WO2021127184A1 (en) * 2019-12-17 2021-06-24 The Johns Hopkins University MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING

Also Published As

Publication number Publication date
CN118541396A (zh) 2024-08-23
IL313491A (en) 2024-08-01
JP2024546923A (ja) 2024-12-26
MX2024007456A (es) 2024-09-10
CA3242393A1 (en) 2023-06-22
WO2023114430A1 (en) 2023-06-22
EP4448583A4 (en) 2025-12-17
AU2022415459A1 (en) 2024-07-04
US20250034252A1 (en) 2025-01-30
EP4448583A1 (en) 2024-10-23

Similar Documents

Publication Publication Date Title
US11155596B2 (en) Polypeptide
JP2023002706A (ja) 抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法
US20230190796A1 (en) Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
US10364280B2 (en) Polypeptide
EA029987B1 (ru) Антитела к cd33 и их применение в лечении рака
JP2022527151A5 (https=)
US20260028409A1 (en) Antibodies that bind to human ccr8
KR102887692B1 (ko) 항-bcam 항체 또는 그의 항원 결합 단편
CA3211203A1 (en) Methods and materials for treating clonal t cell expansions
US20250034252A1 (en) Manabodies targeting p53 tumor antigens and methods of using
KR20240058149A (ko) Vista 항원-결합 분자를 사용한 암의 치료 및 예방
JP7813235B2 (ja) ＮＰＭ１ｃ陽性がんの免疫療法のための組成物および方法
CN115368457A (zh) 抗tigit抗体及其用途
CA3156540A1 (en) Humanized anti-ca ix antibodies and methods of their use
CN119505001B (zh) 靶向cd22的全人源抗体及其应用
US20250334578A1 (en) Cd123 and cd200 as markers for the diagnosis and immune-eradication of leukemic stem cells (lscs)
BR112018007154B1 (pt) Polipeptídeo de ligação a pd-l1, proteína de fusão, conjugado, complexo, composição compreendendo um polipeptídeo de ligação a pdl1, composição compreendendo uma proteína de fusão, composição compreendendo um conjugado e composição compreendendo um complexo
HK1255250B (en) New polypeptide having affinity to pd-l1
NZ741586B2 (en) New polypeptide having affinity to pd-l1

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000